Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Of 22 evaluable patients with hormone refractory prostate cancer in a 26-patient dose escalation Phase
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury